Wegovy HD: A New Era in Obesity Treatment?
The FDA has approved a higher dose of Wegovy (semaglutide), now branded as Wegovy HD (7.2 mg), offering a significant leap forward in obesity management. Results from the STEP UP trial demonstrate an average weight reduction of approximately 21% at 72 weeks for individuals on the higher dose, compared to around 2% for those receiving a placebo. This approval expands Wegovy’s already robust profile, setting it apart from other GLP-1 weight loss medications.
Understanding the STEP UP Trial Results
The STEP UP trial, a phase 3b randomized, double-blind study involving 1,407 adults with obesity (BMI of 30 kg/m2 or greater) without diabetes, revealed compelling data. Participants receiving Wegovy HD experienced an average weight loss of around 19% even when accounting for those who didn’t adhere to the full treatment regimen. Notably, about one in three participants on Wegovy HD achieved a weight loss of 25% or higher. These findings underscore the potential of the higher dose to deliver substantial and lasting results.
|
STEP UP Trial Results (at 72 weeks1, 2)
|
||||
|
Wegovy® injection |
Wegovy® injection |
Placebo |
||
|
Average |
If all patients stayed (Efficacy |
~21% (20.7%) |
~18% (17.5%) |
~2% (2.4%) |
|
Analysis of all (Treatment regimen |
~19% (18.8%) |
~16% (15.5%) |
~4% (3.9%) |
|
|
Percent of patients |
31.2 % |
15.3 % |
0 % |
|
Beyond Weight Loss: Cardiovascular Benefits
Wegovy distinguishes itself from other GLP-1 medications by demonstrating proven cardiovascular benefits. It’s the only GLP-1 approved to reduce the risk of stroke, heart attack, or cardiovascular death in adults with established heart disease and obesity. This dual benefit – weight loss and cardiovascular protection – positions Wegovy as a comprehensive treatment option for a significant patient population.
Accessibility and Availability
Wegovy HD will be available in April, expanding access through existing channels including pharmacies like CVS and Costco, telehealth providers, and NovoCare® Pharmacy. Novo Nordisk is likewise working to provide information on coverage and savings programs for eligible patients.
Frequently Asked Questions (FAQ)
Q: Who is Wegovy HD for?
A: Wegovy HD is for adults with obesity who have tolerated a 2.4 mg dosage for at least four weeks and require further weight reduction.
Q: What are the potential side effects of Wegovy HD?
A: Potential side effects include nausea, diarrhea, vomiting, constipation, and stomach pain. More serious, though rare, side effects include pancreatitis and gallbladder problems.
Q: How does Wegovy HD compare to other weight loss medications?
A: Wegovy HD has demonstrated superior weight loss results compared to placebo and the 2.4 mg dose of Wegovy in the STEP UP trial. This proves also the only GLP-1 medication with proven cardiovascular benefits.
Q: Is Wegovy HD available now?
A: Wegovy HD will be available in April.
* Based on the efficacy estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies.
** Based on the treatment regimen estimand: treatment effect regardless of whether patients stayed on treatment or took other weight loss therapies.
Disclaimer: This article is based on publicly available information as of March 19, 2026, and should not be considered medical advice. Please consult with a healthcare professional for personalized guidance.
